Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Homeopaths slam RPS stance on homeopathy as ill-conceived

Homeopaths have denounced the Royal Pharmaceutical Society’s stance on homeopathy as “ill-conceived, ill-informed and clearly unworkable”.

Last week the RPS said that homeopathy was “clearly not” medicine and should be labelled with warnings there is no scientific evidence for homeopathy.

However, the Faculty of Homeopathy has hit back, stating the RPS statement, which came in response to an MHRA consultation, showed a “disappointing misunderstanding” of evidence.

“Is the RPS seriously suggesting that a product that does not have evidence that satisfies some arbitrary standard of theirs (a standard incidentally, they have no power to set) should be labelled in such a way?” the Faculty of Homeopathy response asks.

The statement is available in full on the Faculty of Homeopathy website.


More analysis of the issue is available in C+D's clinical debate: forget homeopathy, try yoghurt.

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD013414

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel